Research article · 6 Nov 2025
Conference abstractPublished 3 Oct 2022
The role of nuclear medicine in Differentiated Thyroid Cancer (DTC)
Indriati General Hospital, Indonesia
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Thyroid cancer is one of the most common malignant tumors in the endocrine system with estimated incidence of 0.01% to 0.03% per year. It is 3 times more common in women than in men. There are three histologic types of thyroid cancer with DTC as the most common type (around 80% to 90% of all thyroid cancer). This cancer has a 10-year survival rates above 90% if treated adequately which involved surgery, radioactive iodine and thyroid hormone suppression. Theragnostic is an invaluable tool in personalized medicine. Radioactive iodine is the first theragnostic agent used on DTC and its metastases. A study conducted by El Mazzaferi et al. (2001) concluded that radioactive iodine therapy decrease the recurrence rate up to 5 times compared to patients who only received thyroid hormone suppression therapy after surgery. Radioactive iodine therapy is given based on risk stratification system. One of the most common used risk stratification is American Thyroid Association (ATA) risk stratification which divided the risk as low, intermediate and high risk. Hospitalization in isolation room is required for patients who received more than 30 mCi of radioactive iodine. In conclusion, thyroid cancer is a slow growing tumor with high survival rates as long as adequately treated. Nuclear medicine has a theragnostic role in the treatment of thyroid cancer. By using radioactive iodine, thyroid cancer and its metastases could be diagnosed and treated.
Subjects
Diabetes & EndocrinologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Thyroid Disorders & Therapy.
Case report · 18 Jan 2025
Teprotumumab's Efficacy for Recurrent Severe Thyroid Eye Disease Post-Tocilizumab and Steroid Therapy
Short communication · 26 Dec 2024
Thyroid Dysfunction and Its Correlation with Gut Microbiota Dysbiosis
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Thyroid Disorders & Therapy
- SubjectDiabetes & Endocrinology
- BylineArticles whose byline prints “Andreas Lim”
